Routine clinical utility of honeybee venom allergen components.

Since 2010 to 2014, the ImmunoCAP rApi m 1 was the only honeybee venom (HBV) allergen component commercially available for component-resolved diagnostics (CRD) of honeybee venom allergy. Its clinical utility was limited by insufficient sensitivity (ranging from 57% to 82%)1-4 and led to the search for additional HBV components to improve the overall diagnostic sensitivity of CRD in HBV-allergic patients.5 Finally, a broader spectrum of HBV allergen components has become recently commercially available.